Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhishen Yuanhu anticoagulant formula is a Traditional Chinese Medicine (TCM) decoction developed by Luzhou People's Hospital for the prevention of venous thromboembolism (VTE) in patients with malignant tumors. The formula is designed to address the "blood stasis" and hypercoagulable states often observed in cancer patients, particularly those at intermediate-to-high risk for thrombotic events. It is typically evaluated in clinical trials as an alternative or adjunct to standard anticoagulants like low molecular weight heparin (LMWH). The formula's name indicates the inclusion of *Salvia miltiorrhiza* (Zhishen/Danshen) and *Corydalis yanhusuo* (Yuanhu), herbs traditionally used in TCM to promote blood circulation, resolve stasis, and alleviate pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhishen Yuanhu anticoagulant formula.